Emerging treatments
Biological therapies
Research is currently focused on new treatment regimens that incorporate personalised biological therapies for high-risk renal tumours.[3] Limitations to progressing these therapies include the rarity of clinical cases, the genetic heterogeneity of Wilms' tumour, and the low number of actionable somatic mutations. Identification of robust prognostic factors requires extensive international collaborative studies because of the low proportion of individuals with Wilms' tumour who relapse or die.[97] Patients with relapsed Wilms' tumour should undergo thorough molecular characterisation and be enrolled in protocols or trials with systematic data collecting and reporting.[100]
Use of this content is subject to our disclaimer